[
  {
    "ts": null,
    "headline": "Grail’s Stock Dropped 50% on Friday. Investors Still Have High Hopes for the Biotech.",
    "summary": "Grail’s  highflying stock got cut in half last Friday.  The diagnostics company’s stock climbed fivefold last year, in part on expectations for a U.K. national study of Grail’s blood test that detects dozens of cancers before they are symptomatic.  Annual screenings of 140,000 older Brits was hoped to reduce the number of late-stage cancers appearing in the group, after three years.",
    "url": "https://finnhub.io/api/news?id=b2c4ad6ff92b7e078bf63bed3f5a31580c946ad8bd85c2cc3029eedce8d0145c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772143200,
      "headline": "Grail’s Stock Dropped 50% on Friday. Investors Still Have High Hopes for the Biotech.",
      "id": 139240958,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Grail’s  highflying stock got cut in half last Friday.  The diagnostics company’s stock climbed fivefold last year, in part on expectations for a U.K. national study of Grail’s blood test that detects dozens of cancers before they are symptomatic.  Annual screenings of 140,000 older Brits was hoped to reduce the number of late-stage cancers appearing in the group, after three years.",
      "url": "https://finnhub.io/api/news?id=b2c4ad6ff92b7e078bf63bed3f5a31580c946ad8bd85c2cc3029eedce8d0145c"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Abbott Laboratories (ABT) Valuation After Mixed Share Performance And Conflicting Fair Value Signals",
    "summary": "Recent performance snapshot Abbott Laboratories (ABT) has seen mixed share performance recently, with a modest 0.2% move over the past day and a 1.3% gain over the past week, closing at $114.76. Over longer periods, the stock shows a 5.5% return over the past month, a 10.7% decline in the past 3 months, and a 7.6% decline year to date, contributing to a 14.0% negative 1 year total return. See our latest analysis for Abbott Laboratories. For Abbott Laboratories, short term momentum has...",
    "url": "https://finnhub.io/api/news?id=7eca3833358598cbaf50b68df9ad3f4b72f08412ed61707cd07fdf0eecc3011a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772136748,
      "headline": "Assessing Abbott Laboratories (ABT) Valuation After Mixed Share Performance And Conflicting Fair Value Signals",
      "id": 139239892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Recent performance snapshot Abbott Laboratories (ABT) has seen mixed share performance recently, with a modest 0.2% move over the past day and a 1.3% gain over the past week, closing at $114.76. Over longer periods, the stock shows a 5.5% return over the past month, a 10.7% decline in the past 3 months, and a 7.6% decline year to date, contributing to a 14.0% negative 1 year total return. See our latest analysis for Abbott Laboratories. For Abbott Laboratories, short term momentum has...",
      "url": "https://finnhub.io/api/news?id=7eca3833358598cbaf50b68df9ad3f4b72f08412ed61707cd07fdf0eecc3011a"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories stock outperforms competitors on strong trading day",
    "summary": "Abbott Laboratories stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=08411785a98483474cd55ccf9aca10a63da4befd208007ed82d82c36b26316bb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772123640,
      "headline": "Abbott Laboratories stock outperforms competitors on strong trading day",
      "id": 139252292,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=08411785a98483474cd55ccf9aca10a63da4befd208007ed82d82c36b26316bb"
    }
  },
  {
    "ts": null,
    "headline": "Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now?",
    "summary": "Both ISRG and ABT closed 2025 on a strong note, but Intuitive Surgical's surging procedure growth and innovation may give it the edge for long-term gains.",
    "url": "https://finnhub.io/api/news?id=e3a419bfe91f9c82ced0704b07452a9c3531e31cbadc693ab4fbf383a6f14505",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772122860,
      "headline": "Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now?",
      "id": 139238521,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Both ISRG and ABT closed 2025 on a strong note, but Intuitive Surgical's surging procedure growth and innovation may give it the edge for long-term gains.",
      "url": "https://finnhub.io/api/news?id=e3a419bfe91f9c82ced0704b07452a9c3531e31cbadc693ab4fbf383a6f14505"
    }
  },
  {
    "ts": null,
    "headline": "VivaVision Eyes Hong Kong Listing Before Cash Coffers Dry Up",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=27e59591c97c7e84ceef44218ac215ad1a9532dc810e0eb199c671b0d811b13a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772117185,
      "headline": "VivaVision Eyes Hong Kong Listing Before Cash Coffers Dry Up",
      "id": 139248510,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/26/-26-2-2026-10742-thebambooworks-com.jpeg?width=2048&height=1536",
      "related": "ABT",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=27e59591c97c7e84ceef44218ac215ad1a9532dc810e0eb199c671b0d811b13a"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global Laboratory Informatics Market Size/Share Worth USD 8.21 Billion by 2035 at a 5.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Laboratory Informatics Market size & share revenue was valued at approximately USD 4.89 Billion in 2025 and is expected to reach USD 5.15 Billion in 2026 and is expected to reach around USD 8.21 Billion by 2035, at a CAGR of 5.32% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Abbott Laboratories, Agil",
    "url": "https://finnhub.io/api/news?id=4b3bb51162a1b3cd690e452420b62906e0a96c7e1852135f1af4f6184834ccd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772109000,
      "headline": "[Latest] Global Laboratory Informatics Market Size/Share Worth USD 8.21 Billion by 2035 at a 5.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 139232209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Laboratory Informatics Market size & share revenue was valued at approximately USD 4.89 Billion in 2025 and is expected to reach USD 5.15 Billion in 2026 and is expected to reach around USD 8.21 Billion by 2035, at a CAGR of 5.32% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Abbott Laboratories, Agil",
      "url": "https://finnhub.io/api/news?id=4b3bb51162a1b3cd690e452420b62906e0a96c7e1852135f1af4f6184834ccd1"
    }
  },
  {
    "ts": null,
    "headline": "Immunoassay for Neurological Biomarkers Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030",
    "summary": "The market for immunoassays targeting neurological biomarkers is driven by the global rise in neurological disorders, increasing demand for early diagnostics, AI integration enhancing biomarker detection, and personalized therapies. Challenges include regulatory hurdles and standardization complexity. Key players include QIAGEN NV, Abbott, and Merck. Immunoassay for Neurological Biomarkers Market Immunoassay for Neurological Biomarkers Market Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The \"Immuno",
    "url": "https://finnhub.io/api/news?id=8eb35758f7955720bbbd2d670484763dbd968cc6c076ad5441589a2a5fabb5ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772105580,
      "headline": "Immunoassay for Neurological Biomarkers Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030",
      "id": 139230952,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The market for immunoassays targeting neurological biomarkers is driven by the global rise in neurological disorders, increasing demand for early diagnostics, AI integration enhancing biomarker detection, and personalized therapies. Challenges include regulatory hurdles and standardization complexity. Key players include QIAGEN NV, Abbott, and Merck. Immunoassay for Neurological Biomarkers Market Immunoassay for Neurological Biomarkers Market Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The \"Immuno",
      "url": "https://finnhub.io/api/news?id=8eb35758f7955720bbbd2d670484763dbd968cc6c076ad5441589a2a5fabb5ac"
    }
  },
  {
    "ts": null,
    "headline": "Looking Into Abbott Laboratories's Recent Short Interest",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=d3e547265ca511d1c231ae75603ddbf18698dd1198c87933d4750c51503ef5f4",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772100043,
      "headline": "Looking Into Abbott Laboratories's Recent Short Interest",
      "id": 139232890,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536",
      "related": "ABT",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=d3e547265ca511d1c231ae75603ddbf18698dd1198c87933d4750c51503ef5f4"
    }
  },
  {
    "ts": null,
    "headline": "Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects",
    "summary": "Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects",
    "url": "https://finnhub.io/api/news?id=4f8d196010e39ebc0fd4c221a2bcc44632d486f6acd96a208a007dc4f83a9b35",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772087240,
      "headline": "Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects",
      "id": 139230806,
      "image": "",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4f8d196010e39ebc0fd4c221a2bcc44632d486f6acd96a208a007dc4f83a9b35"
    }
  }
]